This week in therapeutics




Licensing status

Publication and contact information



Transforming growth factor-b1 (TGFB1); transforming growth factor-b receptor 1 (TGFBR1; ALK5); TGFBR2

Studies in human samples suggest inhibiting TGFBR1 or TGFBR2 could help treat allergy-related conditions. In 58 patients with Loeys-Dietz syndrome (LDS), a monogenic condition associated with mutations in the genes encoding TGFB1 or the TGFBR1 and TGFBR2 receptors, incidences of allergy-related conditions including asthma, food allergy, rhinitis, eczema and functional gastrointestinal disorders were increased compared with those in the general population. In patient samples, TGFBR1 and TGFBR2 signaling activity and markers of allergies were greater than those in healthy controls. Next steps could include testing TGFB1 inhibitors in allergy models.
Eli Lilly and Co.'s LY2157299, an inhibitor of TGFBR1 and TGFBR2, is in Phase II testing to treat various cancers.

SciBX 6(33); doi:10.1038/scibx.2013.895
Published online Aug. 29, 2013

Patent and licensing status unavailable

Frischmeyer-Guerrerio, P.A. et al. Sci. Transl. Med.; published online
July 24, 2013;
Contact: Harry C. Dietz, The Johns Hopkins University School of Medicine, Baltimore, Md.